Comparison 1. Antifibrinolytic treatment versus control treatment with or without placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Poor outcome (death, vegetative or severe disability on Glasgow Outcome Scale at end of follow‐up): open versus blind studies	4	1546	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.91, 1.15]
1.1 Trials with control treatment (open studies)	1	505	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.64, 1.14]
1.2 Trials with placebo treatment (blind studies)	3	1041	Risk Ratio (M‐H, Random, 95% CI)	1.06 [0.93, 1.21]
2 Death from all causes at end of follow up: open versus blind studies	10	1904	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.85, 1.18]
2.1 Trials with control treatment (open studies)	4	709	Risk Ratio (M‐H, Random, 95% CI)	0.89 [0.56, 1.42]
2.2 Trials with placebo treatment (blind studies)	6	1195	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.87, 1.19]
3 Rebleeding reported at end of follow up: open versus blind studies	10	1904	Risk Ratio (M‐H, Random, 95% CI)	0.65 [0.44, 0.97]
3.1 Trials with control treatment (open studies)	4	709	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.25, 1.74]
3.2 Trials with placebo treatment (blind studies)	6	1195	Risk Ratio (M‐H, Random, 95% CI)	0.64 [0.43, 0.97]
4 Confirmed rebleeding at end of follow‐up (sensitivity analysis): open versus blind studies	4	1505	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.26, 0.75]
4.1 Trials with control treatment (open studies)	2	564	Risk Ratio (M‐H, Random, 95% CI)	0.42 [0.11, 1.59]
4.2 Trials with placebo treatment (blind studies)	2	941	Risk Ratio (M‐H, Random, 95% CI)	0.46 [0.25, 0.86]
5 Rebleeding reported at end of follow‐up: trials with and without ischaemia prevention according to treatment duration	10	1904	Risk Ratio (M‐H, Random, 95% CI)	0.65 [0.44, 0.97]
5.1 Trials without ischaemia prevention, treatment duration > 72 hours	8	937	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.47, 1.31]
5.2 Trials with ischaemia prevention treatment duration > 72 hours	1	462	Risk Ratio (M‐H, Random, 95% CI)	0.58 [0.42, 0.80]
5.3 Trials with ischaemia prevention, treatment duration < 72 hours	1	505	Risk Ratio (M‐H, Random, 95% CI)	0.22 [0.09, 0.52]
6 Cerebral ischaemia reported at end of follow‐up: open versus blind studies	6	1671	Risk Ratio (M‐H, Random, 95% CI)	1.41 [1.04, 1.91]
6.1 Trials with control treatment (open studies)	3	630	Risk Ratio (M‐H, Random, 95% CI)	1.46 [0.99, 2.14]
6.2 Trials with placebo treatment (blind studies)	3	1041	Risk Ratio (M‐H, Random, 95% CI)	1.38 [0.87, 2.19]
7 Confirmed cerebral ischaemia at end of follow‐up (sensitivity analysis): open versus blind studies	3	1000	Risk Ratio (M‐H, Random, 95% CI)	1.34 [0.88, 2.03]
7.1 Trials with control treatment (open studies)	1	59	Risk Ratio (M‐H, Random, 95% CI)	2.58 [0.76, 8.77]
7.2 Trials with placebo treatment (blind studies)	2	941	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.82, 1.89]
8 Hydrocephalus reported at end of follow‐up: open versus blind studies	5	1179	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.90, 1.36]
8.1 Trials with control treatment (open studies)	2	138	Risk Ratio (M‐H, Random, 95% CI)	0.64 [0.34, 1.18]
8.2 Trials with placebo treatment (blind studies)	3	1041	Risk Ratio (M‐H, Random, 95% CI)	1.19 [0.95, 1.48]
9 Confirmed hydrocephalus at end of follow up (sensitivity analysis): open versus blind studies	1	462	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.87, 1.55]
9.1 Trials with control treatment (open studies)	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
9.2 Trials with placebo treatment (blind studies)	1	462	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.87, 1.55]
10 Hydrocephalus reported at end of follow‐up: trials with and without ischaemia prevention according to treatment duration	5	1179	Risk Ratio (M‐H, Random, 95% CI)	1.11 [0.90, 1.36]
10.1 Trials without ischaemia prevention, treatment duration > 72 hours	4	717	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.74, 1.43]
10.2 Trials with ischaemia prevention, treatment duration > 72 hours	1	462	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.87, 1.55]
10.3 Trials with ischaemia prevention, treatment duration < 72 hours	0	0	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
11 Poor outcome (death, vegetative or severe disability on Glasgow Outcome Scale at end of follow‐up): trials with and without ischaemia prevention according to treatment duration	4	1546	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.91, 1.15]
11.1 Trials without cerebral ischaemia prevention, treatment duration > 72 hours	2	579	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.86, 1.22]
11.2 Trials with ischaemia prevention, treatment duration > 72 hours	1	462	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.91, 1.34]
11.3 Trials with cerebral ischaemia prevention, treatment duration < 72 hours	1	505	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.64, 1.14]
12 Death from all causes at end of follow‐up: trials with and without ischaemia prevention according to treatment duration	10	1904	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.85, 1.18]
12.1 Trials without ischaemia prevention, treatment duration > 72 hours	8	937	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.78, 1.35]
12.2 Trials with ischaemia prevention with treatment duration > 72 hours	1	462	Risk Ratio (M‐H, Random, 95% CI)	1.03 [0.79, 1.34]
12.3 Trials with ischaemia prevention with treatment duration < 72 hours	1	505	Risk Ratio (M‐H, Random, 95% CI)	0.83 [0.52, 1.35]
13 Cerebral ischaemia reported at end of follow‐up: trials with and without ischaemia prevention according to treatment duration	6	1671	Risk Ratio (M‐H, Random, 95% CI)	1.41 [1.04, 1.91]
13.1 Trials without ischaemia prevention, treatment duration > 72 hours	4	704	Risk Ratio (M‐H, Random, 95% CI)	1.77 [1.30, 2.40]
13.2 Trials with ischaemia prevention, treatment duration > 72 hours	1	462	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.75, 1.23]
13.3 Trials with ischaemia prevention, treatment duration < 72 hours	1	505	Risk Ratio (M‐H, Random, 95% CI)	1.35 [0.89, 2.04]